Know Cancer

or
forgot password

Treatment of Systemic Mastocytosis With Tamoxifen


N/A
21 Years
N/A
Open (Enrolling)
Both
Systemic Mastocytosis

Thank you

Trial Information

Treatment of Systemic Mastocytosis With Tamoxifen


Not desired


Inclusion Criteria:



- Systemic Mastocytosis

Exclusion Criteria:

- Current treatment with Imatinib mesylate, cladribine or interferon alpha.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Stability or reduction of the percent bone marrow involvement by mastocytosis, including stable mast cell morphology and phenotype.

Outcome Description:

up to 40% bone marrow infiltration by mast cells and/or 2) mediator-release symptoms which are not controlled by tolerated doses of standard "non-cytotoxic" medications regardless of the percentage bone marrow involvement by mastocytosis. The dose of Tamoxifen will be 20 mg/day and the duration of treatment will be for one year.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

Joseph H Butterfield, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mayo Clinic

Authority:

United States: Institutional Review Board

Study ID:

2506-04

NCT ID:

NCT01334996

Start Date:

February 2005

Completion Date:

December 2013

Related Keywords:

  • Systemic Mastocytosis
  • Mastocytosis
  • Urticaria Pigmentosa
  • Mastocytoma
  • Mastocytosis, Systemic

Name

Location

Mayo ClinicRochester, Minnesota  55905